Plain-English translation of NCT05775159 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 2 β Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing two new medications called and that work by boosting your immune system to fight cancer. These medications will be tested either by themselves or combined with other approved cancer treatments in people with advanced hepatocellular carcinoma (a type of liver cancer) or biliary tract cancer (cancer of the bile ducts). The goal is to see if this treatment approach helps shrink tumors and improve survival.
Advanced liver and bile duct cancers are difficult to treat, and current treatment options don't work for everyone. This trial exists to find out if these new medications, which work differently than traditional chemotherapy by activating the immune system, might offer hope for patients who need better treatment options.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You will receive the study medication either as an injection or infusion, possibly combined with other cancer drugs, depending on which treatment group you are assigned to. You will visit the research clinic regularly for check-ups, blood tests, and imaging scans to monitor how the treatment is working and to check for side effects. The study involves two main groups: one focusing on liver cancer (with about 200 participants) and another focusing on bile duct cancer (with about 90 participants), each testing different medication combinations.
AI-generated summary from trial data Β· Jun 9, 2026 Β· Not medical advice
United States